Close
FINDING CURES TOGETHER<sup>SM</sup>

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival

The Reference Meeting for Scientists, Clinicians, Regulators, Drug Developers, and Patient Advocates

September 16-19, 2015
Sheraton New York Times Square Hotel
New York, New York

With the explosion of interest in cancer immunotherapy and the proliferation of scientific meetings in the field, the time is right for a coordinated effort hosted by the field's leaders. The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to join forces to sponsor the first International Cancer Immunotherapy Conference. This collaborative meeting will be held every other year, in lieu of each organization's individual meeting, and will alternate between the United States and Europe. We believe that by combining our efforts we can be more effective and efficient in disseminating the latest cutting-edge information.

The inaugural meeting will take place at the Sheraton Times Square in New York City on September 16-19, 2015. Entitled "Translating Science into Survival," it will cover all areas of inquiry in cancer immunology and immunotherapy, including:  immune regulation of T cell responsiveness, genomic methods for identifying tumor antigens, the tumor microenvironment, T cell therapies, checkpoint blockade, biomarkers, combinations, and the microbiome. More than 60 talks by acknowledged leaders in these areas will be given.

This joint meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.  We hope this will be the one cancer immunotherapy meeting that you will be sure to attend in 2015.

Scientific Planning Committee
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas
Cedrik M. Britten, GlaxoSmithKline, Stevenage, United Kingdom
Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
Alexander M. M. Eggermont, Institut Gustave Roussy, Paris, France
Carl G. Figdor, Radboud University of Nijmegen, Nijmegen, The Netherlands
Wolf-Hervé Fridman, Centre de Recherche des Cordeliers, Paris, France
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
Axel Hoos, GlaxoSmithKline, Collegeville, Pennsylvania
Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, Maryland
Peter W. M. Johnson, University of Southampton, Southampton, United Kingdom
Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France
Nils Lonberg, Bristol-Myers Squibb, Milpitas, California
Cornelis J. M. Melief, Leiden University Medical Center, Leiden, The Netherlands
Ellen Puré, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania
Robert D. Schreiber, Washington University, St. Louis, Missouri


Diamond Supporter
Bristol-Myers Squibb

Platinum Supporter
Roche

Silver Supporters
Amgen    Genentech
Miltenyi Biotec   Regeneron

Supporters
Doris Duke Foundation
Gilead    Lilly Oncology

Professional Educational Grants
AbbVie   AstraZeneca   Celgene   Genentech
Gilead   Incyte   Lilly   Merck   Novartis

Continuing Medical Education Activity – AMA PRA Category 1 Credits™ available

#cicon15